Status:
TERMINATED
Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
Androgen deprivation therapy (ADT) is considered standard of care for prostate cancer. However, changes in the patients metabolism are usually seen as a result of hormone therapy. These changes includ...
Detailed Description
* Participants will be asked to come into the clinic for additional visits before they begin hormone therapy. The following procedures will be performed: Cold-activated PET/CT scan; body composition D...
Eligibility Criteria
Inclusion
- Adenocarcinoma of the prostate
- Scheduled to initiate GnRH agonist or antagonist treatment with an intended treatment duration of 12 months or greater
- ECOG Performance status of 0 or 1
- Ability to understand and the willingness to sign a written informed consent
- 65 years of age or younger
Exclusion
- Diagnosis of diabetes
- Ongoing corticosteroid use
- GnRH agonist or antagonist treatment within the last 2 years
- Ongoing beta-blocker use
- Body mass index of greater than 30
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01226888
Start Date
September 1 2010
End Date
October 1 2012
Last Update
November 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02214